Suchergebnisse - "Laharie, David"

PubPharm (55)

1

Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy

enthalten in: Pharmacotherapy | 2024

von Alizadeh, E. | Dervieux, T. | Vermeire, S. | +5

2

Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease : The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif

enthalten in: Clinical and translational gastroenterology | 2023

von Guillo, L. | Savoye, G. | Amiot, A. | +22

CommentIn: Clin Transl Gastroenterol. 2023 Dec 01;14(12):e00618. - PMID 38156785

3

Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab : when the remission state hides different types of residual disease activity

enthalten in: Gut | 2023

von Pierre, N. | Huynh-Thu, V. | Marichal, T. | +8

4

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE) : a multicentre, open-label, randomised controlled trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Louis, E. | Resche-Rigon, M. | Laharie, D. | +49

CommentIn: Lancet Gastroenterol Hepatol. 2023 Mar;8(3):200-201. - PMID 36640793

5

The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics

enthalten in: Frontiers in immunology | 2023

von Lelong, M. | Josien, R. | Coste-Burel, M. | +23

6

Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis : The GETAID FOCUS Study

enthalten in: Digestive diseases and sciences | 2022

von Guillo, L. | Amiot, A. | Serrero, M. | +46

CommentIn: Dig Dis Sci. 2022 Sep;67(9):4326-4329. - PMID 35304651

7

Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression : Long-Term Data From the TAILORIX Trial

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Laharie, D. | D'Haens, G. | Nachury, M. | +16

CommentIn: Clin Gastroenterol Hepatol. 2022 Nov;20(11):2654-2655. - PMID 34968727

8

Efficacy and Safety of Infliximab Retreatment in Crohn's Disease : A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID

enthalten in: The American journal of gastroenterology | 2022

von Boschetti, G. | Nachury, M. | Laharie, D. | +18

9

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST) : an open-label, multicentre, randomised phase 3b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Danese, S. | Vermeire, S. | D'Haens, G. | +99

CommentIn: Lancet Gastroenterol Hepatol. 2022 Apr;7(4):276-277. - PMID 35120657

10

Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer

enthalten in: Gut microbes | 2022

von Lavelle, A. | Nancey, S. | Reimund, J. | +17

1
2
3
4
5
6
Nächster »
[6]